pharma news today obesity drugs glp-1 Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began. Having Federal regulators on Wednesday approved
Description
doi:10.1111/j.1463-1326.2012.01663.x 17
But Pfizer seems to have concluded that the toxicity question mark would damage its ability to compete in a relatively crowded space
Tirzepatide is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss in clinical trialsaveraging 22.5% of body weight over 72 weeks
10.1016/j.cmet.2017.04.013 27 GreinerT
doi: 10.1517/13543780902766802 119 ZhangYLiYZhaoJWangCDengBZhangQet al
Muscle matters: the effects of medically induced weight loss on skeletal muscle
